When a small amount of Gram-negative lipopolysaccharide was intravenously injected into mice which had been injected with heat-killed Propionibacterium acnes 7 days before, massive hepatic cell necrosis was induced and most of the mice died 24 hr later. However, when prostaglandin E1 was administered with lipopolysaccharide, remarkable improvements in the survival rate and in the histological changes of the liver were observed. In order to find out how prostaglandin E1 suppressed the induction of massive hepatic cell necrosis in this experimental model, we studied the effects of prostaglandin E1 on the activation of liver adherent cells, from which the cytotoxic factor is released, and on the protection of hepatocytes from the cytotoxic factor. As a result, prostaglandin E1 not only inhibited the activation of liver adherent cells and suppressed the release of the cytotoxic factor, but it also directly affected the hepatocytes and protected them from the cytotoxic factor.
The contamination level of antineoplastic drugs was suggested to be related with the amount of drugs handled, cleaning methods of the equipment, and the skill level of the technique of maintaining negative pressure inside a vial. In order to reduce the contamination and exposure to antineoplastic drugs in the hospital work environment very close to zero, comprehensive safety precautions, including adequate mixing and cleaning methods was required in addition to BSC and closed system device.
Object: To study the effects of the intravenous administration of methylcobalamin, an analogue of vitamin B12, for uremic or uremic-diabetic polyneuropathy in patients whoare receiving maintenance hemodialysis. An ultra-high dose of vitamin B12 has been reported to promote peripheral nerve regeneration in experimental neuropathy. Methods: Nine patients received a 500|ig methylcobalamin injection 3 times a week for 6 months. The effects were evaluated using neuropathic pain grading and a nerve conduction study. Results: Serum concentrations of vitamin B12 were ultra-high during treatment due to the lack of urinary excretion. After 6 months of treatment, the patients' pain or paresthesia had lessened, and the ulnar motor and median sensory nerve conduction velocities showed significant improvement. There were no side effects. Conclusion: Intravenous methycobalamin treatment is a safe and potentially beneficial therapy for neuropathy in chronic hemodialysis patients. (Internal Medicine 38: 472-475, 1999)
In order to clarify the bioavailability of lead in plasma (PbP), we performed a study on five workers in a Japanese factory manufacturing lead glass-based paints. Blood and urine samples were obtained over a period of 15 months, during which time the workers took it in turns to perform sifting work (with the highest level of lead exposure) for 1-month periods. A total of 75 sets of blood and urine samples were thus obtained. We determined whole blood lead (PbB), PbP, Urinary coproporphyrin (CPU), urinary delta-aminolevulinic acid (ALAU), urinary lead (PbU) and ALA in plasma (ALAP). In the 15 sets of samples obtained at the end of the period with a high level of lead exposure, PbP correlated significantly with ALAU, CPU, PbU and ALAP, but PbB correlated significantly only with PbU. In the 60 sets of samples obtained following a low level of lead exposure, correlation coefficients between the concentrations of PbP and of ALAU, CPU and PbU exceeded those between the concentrations of PbB and of ALAU, CPU and PbU. These findings indicate that PbP is a better dose indicator of lead biochemically available for heme synthesis and that PbU has a closer correlation with PbP than with PbB.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.